Skip to main content
Top
Published in: Multidisciplinary Respiratory Medicine 1/2012

Open Access 01-12-2012 | Original research article

Endotoxin markers in bronchoalveolar lavage fluid of patients with interstitial lung diseases

Authors: Bogumiła Szponar, Lennart Larsson, Joanna Domagała-Kulawik

Published in: Multidisciplinary Respiratory Medicine | Issue 1/2012

Login to get access

Abstract

Background

Exposure to inhaled endotoxins (lipopolysaccharides, LPS) of Gram-negative bacteria commonly found in indoor environments and assessed in secondary tobacco smoke, has been associated with airway inflammation and asthma exacerbation. The bronchoalveolar lavage fluid (BALf) from patients with interstitial lung diseases (sarcoidosis, lung fibrosis, smoking-related ILD, eosinophilic disorders) was analyzed for the markers of lipopolysaccharide (LPS, endotoxin).

Methods

BALf was obtained from patients with diffuse lung diseases: idiopathic pulmonary fibrosis (n = 42), sarcoidosis (n = 22), smoking-related-ILD (n = 11) and eosinophilic disorders (n = 8). Total cell count and differential cell count were performed. In addition, samples were analyzed for 3-hydroxy fatty acids (3-OHFAs) of 10–18 carbon chain lengths, as markers of LPS, by gas chromatography-tandem mass spectrometry.

Results

The highest LPS concentration was found in patients with eosinophilic disorders and the lowest in patients with sarcoidosis (p< 0.05) followed by the lung fibrosis and the sr-ILD patients. The difference between LPS in BALf with extremely high eosinophil proportion (> 25%) and those with lower proportion was also significant (p = 0.014). A significant correlation was found between LPS and eosinophils, but not between LPS and lymphocytes, neutrophils, or macrophages count.

Conclusions

A positive relationship of LPS and eosinophilic pulmonary disorders may be linked to a persistent eosinophil activation mediated by Th2 pathway: chronic endotoxin exposure would intensify Th2 pathway resulting in fibrosis and, at the same time, eosinophil stimulation, and hence in eosinophilic pulmonary disorders.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kharitonov SA, Sjöbring U: Lipopolysaccharide challenge of humans as a model for chronic obstructive lung disease exacerbations. Contrib Microbiol. 2007, 14: 83-100.CrossRefPubMed Kharitonov SA, Sjöbring U: Lipopolysaccharide challenge of humans as a model for chronic obstructive lung disease exacerbations. Contrib Microbiol. 2007, 14: 83-100.CrossRefPubMed
2.
go back to reference Hines CJ, Milton DK, Larsson L, Petersen MR, Fisk WJ, Mendell MJ: Characterization and variability of endotoxin and 3-hydroxy fatty acids in an office building during a particle intervention study. Indoor Air. 2000, 10: 2-12. 10.1034/j.1600-0668.2000.010001002.x.CrossRefPubMed Hines CJ, Milton DK, Larsson L, Petersen MR, Fisk WJ, Mendell MJ: Characterization and variability of endotoxin and 3-hydroxy fatty acids in an office building during a particle intervention study. Indoor Air. 2000, 10: 2-12. 10.1034/j.1600-0668.2000.010001002.x.CrossRefPubMed
3.
go back to reference Kärkkäinen PM, Valkonen M, Hyvärinen A, Nevalainen A, Rintala H: Determination of bacterial load in house dust using qPCR, chemical markers and culture. J Environ Monit. 2010, 12: 759-768. 10.1039/b917937b.CrossRefPubMed Kärkkäinen PM, Valkonen M, Hyvärinen A, Nevalainen A, Rintala H: Determination of bacterial load in house dust using qPCR, chemical markers and culture. J Environ Monit. 2010, 12: 759-768. 10.1039/b917937b.CrossRefPubMed
4.
go back to reference Poole JA, Dooley GP, Saito R, Burrell AM, Bailey KL, Romberger DJ, Mehaffy J, Reynolds SJ: Muramic acid, endotoxin, 3-hydroxy fatty acids, and ergosterol content explain monocyte and epithelial cell inflammatory responses to agricultural dusts. J Toxicol Environ Health A. 2010, 73: 684-700. 10.1080/15287390903578539.PubMedCentralCrossRefPubMed Poole JA, Dooley GP, Saito R, Burrell AM, Bailey KL, Romberger DJ, Mehaffy J, Reynolds SJ: Muramic acid, endotoxin, 3-hydroxy fatty acids, and ergosterol content explain monocyte and epithelial cell inflammatory responses to agricultural dusts. J Toxicol Environ Health A. 2010, 73: 684-700. 10.1080/15287390903578539.PubMedCentralCrossRefPubMed
5.
go back to reference Lampi J, Roponen M, Hyvärinen A, Hirvonen MR, Larsson L, Nevalainen A, Pekkanen J: Determinants of stimulated peripheral blood cytokine production among farming women. Int J Hyg Environ Health. 2011, 214: 205-209. 10.1016/j.ijheh.2011.01.007.CrossRefPubMed Lampi J, Roponen M, Hyvärinen A, Hirvonen MR, Larsson L, Nevalainen A, Pekkanen J: Determinants of stimulated peripheral blood cytokine production among farming women. Int J Hyg Environ Health. 2011, 214: 205-209. 10.1016/j.ijheh.2011.01.007.CrossRefPubMed
6.
go back to reference Larsson L, Szponar B, Pehrson C: Tobacco smoking increases dramatically air concentrations of endotoxin. Indoor Air. 2004, 14: 421-424. 10.1111/j.1600-0668.2004.00290.x.CrossRefPubMed Larsson L, Szponar B, Pehrson C: Tobacco smoking increases dramatically air concentrations of endotoxin. Indoor Air. 2004, 14: 421-424. 10.1111/j.1600-0668.2004.00290.x.CrossRefPubMed
7.
go back to reference Hasday JD, Bascom R, Costa JJ, Fitzgerald T, Dubin W: Bacterial endotoxin is an active component of cigarette smoke. Chest. 1999, 115: 829-835. 10.1378/chest.115.3.829.CrossRefPubMed Hasday JD, Bascom R, Costa JJ, Fitzgerald T, Dubin W: Bacterial endotoxin is an active component of cigarette smoke. Chest. 1999, 115: 829-835. 10.1378/chest.115.3.829.CrossRefPubMed
8.
go back to reference Domagała-Kulawik J: BAL in the diagnosis of smoking-related interstitial lung diseases: review of literature and analysis of our experience. Diagn Cytopathol. 2008, 36: 909-915. 10.1002/dc.20944.CrossRefPubMed Domagała-Kulawik J: BAL in the diagnosis of smoking-related interstitial lung diseases: review of literature and analysis of our experience. Diagn Cytopathol. 2008, 36: 909-915. 10.1002/dc.20944.CrossRefPubMed
9.
go back to reference Costabel U, Ohshimo S, Guzman J: Diagnosis of sarcoidosis. Curr Opin Pulm Med. 2008, 14: 455-461. 10.1097/MCP.0b013e3283056a61.CrossRefPubMed Costabel U, Ohshimo S, Guzman J: Diagnosis of sarcoidosis. Curr Opin Pulm Med. 2008, 14: 455-461. 10.1097/MCP.0b013e3283056a61.CrossRefPubMed
10.
go back to reference Baughman RP: Technical aspects of bronchoalveolar lavage: recommendations for a standard procedure. Semin Respir Crit Care Med. 2007, 28: 475-485. 10.1055/s-2007-991520.CrossRefPubMed Baughman RP: Technical aspects of bronchoalveolar lavage: recommendations for a standard procedure. Semin Respir Crit Care Med. 2007, 28: 475-485. 10.1055/s-2007-991520.CrossRefPubMed
11.
go back to reference Costabel U: Atlas of bronchoalveolar lavage. Chapman & Hall Media, 1998 Costabel U: Atlas of bronchoalveolar lavage. Chapman & Hall Media, 1998
12.
go back to reference Meyer KC: Bronchoalveolar lavage as a diagnostic tool. Semin Respir Crit Care Med. 2007, 28: 546-560. 10.1055/s-2007-991527.CrossRefPubMed Meyer KC: Bronchoalveolar lavage as a diagnostic tool. Semin Respir Crit Care Med. 2007, 28: 546-560. 10.1055/s-2007-991527.CrossRefPubMed
13.
go back to reference Chciałowski A, Chorostkowska-Wynimko J, Fal A, Pawłowicz R, Domagała-Kulawik J: Recommendation of the Polish Respiratory Society for bronchoalveolar lavage (BAL) sampling, processing and analysis methods. Pneumonol Alergol Pol. 2011, 79: 75-98.PubMed Chciałowski A, Chorostkowska-Wynimko J, Fal A, Pawłowicz R, Domagała-Kulawik J: Recommendation of the Polish Respiratory Society for bronchoalveolar lavage (BAL) sampling, processing and analysis methods. Pneumonol Alergol Pol. 2011, 79: 75-98.PubMed
14.
go back to reference Singh J, Schwartz DA: Endotoxin and the lung: Insight into the host-environment interaction. J Allergy Clin Immunol. 2005, 115: 330-333. 10.1016/j.jaci.2004.11.021.CrossRefPubMed Singh J, Schwartz DA: Endotoxin and the lung: Insight into the host-environment interaction. J Allergy Clin Immunol. 2005, 115: 330-333. 10.1016/j.jaci.2004.11.021.CrossRefPubMed
15.
go back to reference Borchers AT, So C, Naguwa SM, Keen CL, Gershwin ME: Clinical and immunologic components of sarcoidosis. Clin Rev Allergy Immunol. 2003, 25: 289-303. 10.1385/CRIAI:25:3:289.CrossRefPubMed Borchers AT, So C, Naguwa SM, Keen CL, Gershwin ME: Clinical and immunologic components of sarcoidosis. Clin Rev Allergy Immunol. 2003, 25: 289-303. 10.1385/CRIAI:25:3:289.CrossRefPubMed
16.
go back to reference Patel AM, Ryu JH, Reed CE: Hypersensitivity pneumonitis: current concepts and future questions. J Allergy Clin Immunol. 2001, 108: 661-670. 10.1067/mai.2001.119570.CrossRefPubMed Patel AM, Ryu JH, Reed CE: Hypersensitivity pneumonitis: current concepts and future questions. J Allergy Clin Immunol. 2001, 108: 661-670. 10.1067/mai.2001.119570.CrossRefPubMed
17.
go back to reference Seibold MA, Schwartz DA: The lung: the natural boundary between nature and nurture. Annu Rev Physiol. 2011, 73: 457-478. 10.1146/annurev-physiol-012110-142212.CrossRefPubMed Seibold MA, Schwartz DA: The lung: the natural boundary between nature and nurture. Annu Rev Physiol. 2011, 73: 457-478. 10.1146/annurev-physiol-012110-142212.CrossRefPubMed
18.
go back to reference Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J, Crawford JM, Ferrara JL: An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996, 88: 3230-3239.PubMed Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J, Crawford JM, Ferrara JL: An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996, 88: 3230-3239.PubMed
19.
go back to reference Demedts M, Costabel U: ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J. 2002, 19: 794-796. 10.1183/09031936.02.00492002.CrossRefPubMed Demedts M, Costabel U: ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J. 2002, 19: 794-796. 10.1183/09031936.02.00492002.CrossRefPubMed
20.
go back to reference Pozzi E, De Rose V, Rennard SI, Fabbri LM: Clinical guidelines and indications for bronchoalveolar lavage (BAL): Report of the European Society of Pneumology Task Group on BAL. Eur Respir J. 1990, 3: 937-976. Pozzi E, De Rose V, Rennard SI, Fabbri LM: Clinical guidelines and indications for bronchoalveolar lavage (BAL): Report of the European Society of Pneumology Task Group on BAL. Eur Respir J. 1990, 3: 937-976.
21.
go back to reference Larsson L, Saraf A: Use of gas chromatography-ion trap tandem mass spectrometry for the detection and characterization of microorganisms in complex samples. Mol Biotechnol. 1997, 7: 279-287. 10.1007/BF02740818.CrossRefPubMed Larsson L, Saraf A: Use of gas chromatography-ion trap tandem mass spectrometry for the detection and characterization of microorganisms in complex samples. Mol Biotechnol. 1997, 7: 279-287. 10.1007/BF02740818.CrossRefPubMed
22.
go back to reference Ferrando R, Szponar B, Sánchez A, Larsson L, Valero-Guillén PL: 3-Hydroxy fatty acids in saliva as diagnostic markers in chronic periodontitis. J Microbiol Methods. 2005, 62: 285-291. 10.1016/j.mimet.2005.04.014.CrossRefPubMed Ferrando R, Szponar B, Sánchez A, Larsson L, Valero-Guillén PL: 3-Hydroxy fatty acids in saliva as diagnostic markers in chronic periodontitis. J Microbiol Methods. 2005, 62: 285-291. 10.1016/j.mimet.2005.04.014.CrossRefPubMed
23.
go back to reference Kraśnik L, Szponar B, Walczak M, Larsson L, Gamian A: Routine clinical laboratory tests correspond to increased serum levels of 3-hydroxy fatty acids, markers of endotoxins, in cardiosurgery patients. Arch Immunol Ther Exp. 2006, 54: 55-60. 10.1007/s00005-006-0006-2.CrossRef Kraśnik L, Szponar B, Walczak M, Larsson L, Gamian A: Routine clinical laboratory tests correspond to increased serum levels of 3-hydroxy fatty acids, markers of endotoxins, in cardiosurgery patients. Arch Immunol Ther Exp. 2006, 54: 55-60. 10.1007/s00005-006-0006-2.CrossRef
24.
go back to reference Szponar B, Pehrson C, Larsson L: Bacterial and fungal markers in tobacco smoke. Sci Total Environ. 2012, 438: 447-451.CrossRefPubMed Szponar B, Pehrson C, Larsson L: Bacterial and fungal markers in tobacco smoke. Sci Total Environ. 2012, 438: 447-451.CrossRefPubMed
25.
go back to reference Górska K, Krenke R, Korczyński P, Kościuch J, Domagała-Kulawik J, Chazan R: Eosinophilic airway inflammation in chronic obstructive pulmonary disease and asthma. J Physiol Pharmacol. 2008, 59 (Suppl 6): 261-270.PubMed Górska K, Krenke R, Korczyński P, Kościuch J, Domagała-Kulawik J, Chazan R: Eosinophilic airway inflammation in chronic obstructive pulmonary disease and asthma. J Physiol Pharmacol. 2008, 59 (Suppl 6): 261-270.PubMed
26.
go back to reference Costabel U, Guzman J, Bonella F, Oshimo S: Bronchoalveolar lavage in other interstitial lung diseases. Semin Respir Crit Care Med. 2007, 28: 514-524. 10.1055/s-2007-991525.CrossRefPubMed Costabel U, Guzman J, Bonella F, Oshimo S: Bronchoalveolar lavage in other interstitial lung diseases. Semin Respir Crit Care Med. 2007, 28: 514-524. 10.1055/s-2007-991525.CrossRefPubMed
27.
go back to reference Domagała-Kulawik J, Grubek-Jaworska H, Maskey-Warzechowska M, Chazan R: BALf eosinophilia – diagnosticdiagnostics value. 2008, Athens: 9th WASOG Meeting and 11th BAL International Conference Domagała-Kulawik J, Grubek-Jaworska H, Maskey-Warzechowska M, Chazan R: BALf eosinophilia – diagnosticdiagnostics value. 2008, Athens: 9th WASOG Meeting and 11th BAL International Conference
28.
go back to reference Michel O, Nagy AM, Schroeven M, Duchateau J, Nève J, Fondu P, Sergysels R: Dose–response relationship to inhaled endotoxin in normal subjects. Am J Respir Crit Care Med. 1997, 156: 1157-1164.CrossRefPubMed Michel O, Nagy AM, Schroeven M, Duchateau J, Nève J, Fondu P, Sergysels R: Dose–response relationship to inhaled endotoxin in normal subjects. Am J Respir Crit Care Med. 1997, 156: 1157-1164.CrossRefPubMed
29.
go back to reference Wallin A, Pourazar J, Sandström T: LPS-induced bronchoalveolarneutrophilia; effects of salmeterol treatment. Respir Med. 2004, 98: 1087-1092. 10.1016/j.rmed.2004.03.025.CrossRefPubMed Wallin A, Pourazar J, Sandström T: LPS-induced bronchoalveolarneutrophilia; effects of salmeterol treatment. Respir Med. 2004, 98: 1087-1092. 10.1016/j.rmed.2004.03.025.CrossRefPubMed
30.
go back to reference Bozinovski S, Jones J, Beavitt SJ, Cook AD, Hamilton JA, Anderson GP: Innate immune responses to LPS in mouse lung are suppressed and reversed by neutralization of GM-CSF via repression of TLR-4. Am J Physiol Lung Cell Mol Physiol. 2004, 286: L877-885.CrossRefPubMed Bozinovski S, Jones J, Beavitt SJ, Cook AD, Hamilton JA, Anderson GP: Innate immune responses to LPS in mouse lung are suppressed and reversed by neutralization of GM-CSF via repression of TLR-4. Am J Physiol Lung Cell Mol Physiol. 2004, 286: L877-885.CrossRefPubMed
31.
go back to reference Keane MP: The role of chemokines and cytokines in lung fibrosis. Eur Respir Rev. 2008, 17: 151-156. 10.1183/09059180.00010908.CrossRef Keane MP: The role of chemokines and cytokines in lung fibrosis. Eur Respir Rev. 2008, 17: 151-156. 10.1183/09059180.00010908.CrossRef
32.
go back to reference Facco M, Cabrelle A, Teramo A, Olivieri V, Gnoato M, Teolato S, Ave E, Gattazzo C, Fadini GP, Calabrese F, Semenzato G, Agostini C: Sarcoidosisis a Th1/Th17 multisystemdisorder. Thorax. 2011, 66: 144-150. 10.1136/thx.2010.140319.CrossRefPubMed Facco M, Cabrelle A, Teramo A, Olivieri V, Gnoato M, Teolato S, Ave E, Gattazzo C, Fadini GP, Calabrese F, Semenzato G, Agostini C: Sarcoidosisis a Th1/Th17 multisystemdisorder. Thorax. 2011, 66: 144-150. 10.1136/thx.2010.140319.CrossRefPubMed
Metadata
Title
Endotoxin markers in bronchoalveolar lavage fluid of patients with interstitial lung diseases
Authors
Bogumiła Szponar
Lennart Larsson
Joanna Domagała-Kulawik
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Multidisciplinary Respiratory Medicine / Issue 1/2012
Electronic ISSN: 2049-6958
DOI
https://doi.org/10.1186/2049-6958-7-54

Other articles of this Issue 1/2012

Multidisciplinary Respiratory Medicine 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine